食管癌免疫治疗的生物标志物。
Biomarkers for immunotherapy in esophageal cancer.
机构信息
Department of Oncology and Hematology, Zhongxian People's Hospital, Chongqing, China.
Department of Urology, Zhongxian People's Hospital, Chongqing, China.
出版信息
Front Immunol. 2023 May 1;14:1117523. doi: 10.3389/fimmu.2023.1117523. eCollection 2023.
Abstract
The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunotherapy. However, the effects of these reported biomarkers are controversial and many challenges remain. In this review, we aim to summarize the current clinical evidence and provide a comprehensive understanding of the reported biomarkers. We also discuss the limits of the present biomarkers and propose our own opinions on which viewers' discretion are advised.
摘要
免疫疗法的发展，特别是针对 PD-1/PD-L1 的免疫检查点抑制剂，改善了食管癌患者的预后。然而，并非所有人群都能从这些药物中获益。最近，多种生物标志物被引入以预测免疫治疗的反应。然而，这些报道的生物标志物的效果存在争议，仍然存在许多挑战。在这篇综述中，我们旨在总结目前的临床证据，并对报道的生物标志物有一个全面的了解。我们还讨论了目前生物标志物的局限性，并就哪些观点需要谨慎提出了我们自己的看法。
相似文献
1
Biomarkers for immunotherapy in esophageal cancer.
Front Immunol. 2023 May 1;14:1117523. doi: 10.3389/fimmu.2023.1117523. eCollection 2023.
2
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
3
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
4
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
Clin Lung Cancer. 2021 Sep;22(5):381-389. doi: 10.1016/j.cllc.2021.03.006. Epub 2021 Mar 24.
5
PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
J Gene Med. 2021 Feb;23(2):e3294. doi: 10.1002/jgm.3294. Epub 2021 Jan 5.
6
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.
7
[Advances of immunotherapy-related biomarker in esophageal carcinoma].
Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Apr 25;26(4):396-400. doi: 10.3760/cma.j.cn441530-20221213-00522.
8
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
J Immunol Methods. 2021 Mar;490:112956. doi: 10.1016/j.jim.2021.112956. Epub 2021 Jan 9.
9
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
10
Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.
Immunotherapy. 2022 Mar;14(4):249-257. doi: 10.2217/imt-2021-0175. Epub 2022 Jan 25.
引用本文的文献
1
Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.
Clin Transl Oncol. 2025 Sep 6. doi: 10.1007/s12094-025-04051-4.
2
Blood Microbiome Reveals the Impact of on the Efficacy of Immunotherapy in Gastrointestinal Cancer.
MedComm (2020). 2025 Aug 11;6(8):e70316. doi: 10.1002/mco2.70316. eCollection 2025 Aug.
3
Pan-cancer analysis of UGGT1 in human tumors and experimental validation in breast cancer.
Sci Rep. 2025 Jul 24;15(1):26901. doi: 10.1038/s41598-025-12619-x.
4
Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma.
BMC Cancer. 2025 Mar 31;25(1):576. doi: 10.1186/s12885-025-13938-y.
5
Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy.
J Gastrointest Oncol. 2025 Feb 28;16(1):1-16. doi: 10.21037/jgo-24-722. Epub 2025 Feb 26.
6
Predictive value of pretreatment peripheral blood N/CD4 and N/CD8 ratios for the efficacy of radiotherapy for esophageal cancer.
Radiol Oncol. 2025 Mar 19;59(2):257-266. doi: 10.2478/raon-2025-0015. eCollection 2025 Jun 1.
7
Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma.
Am J Transl Res. 2024 Oct 15;16(10):5880-5889. doi: 10.62347/KMCL5401. eCollection 2024.
本文引用的文献
1
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004688.
2
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20.
3
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714.
4
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
5
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3.
6
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
7
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
J Immunol Res. 2021 Dec 28;2021:2549295. doi: 10.1155/2021/2549295. eCollection 2021.
8
Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1243-1255. doi: 10.1016/j.ijrobp.2021.12.162. Epub 2022 Jan 2.
9
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836.
10
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
Zotero 插件